Evidence method
Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue
-2400.27% · OPTIONAL · VALID
GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME
OVID · Jun 30, 2026
Ovid Therapeutics Inc.. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.
STATE CAPABILITYLEVEL 3[email protected]
Inspectable configuration
State dimensions
Filing0001628280-26-056498General Corporate
Evidence method
Yoy · gp.fundamentals.revenue
-88.31% · CORE · VALID
Evidence method
Level · gp.fundamentals.operating_margin
-2141.61% · CORE · VALID
Evidence method
Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue
1358.39% · OPTIONAL · VALID
Evidence method
Level · gp.fundamentals.sbc_revenue_ratio
195.23% · OPTIONAL · VALID
As-filed lineage
Fundamental state history
Each observation is tied to the filing and facts available at that report date. Amendments remain separate.
History10 statesHistory building
Dec 31, 20230/6 normalizedLevel 3Mar 31, 20240/6 normalizedLevel 3Jun 30, 20240/6 normalizedLevel 3Sep 30, 20240/6 normalizedLevel 3Dec 31, 20245/6 normalizedLevel 3Mar 31, 20255/6 normalizedLevel 3Jun 30, 20255/6 normalizedLevel 3Sep 30, 20255/6 normalizedLevel 3Dec 31, 20256/6 normalizedLevel 3Jun 30, 20265/5 normalizedLevel 3
Period transition
What moved in the state?
- Previous
- -100.00%
- Current
- -88.31%
- Delta
- 11.69%
Self-history only
Previous similar states
Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.
Not enough compatible prior states for a transparent self-history match.
Research Graph
Related governed research
Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.